Impact of Voglibose on the Pharmacokinetics of Dapagliflozin in Japanese Patients with Type 2 Diabetes

INTRODUCTION: Dapagliflozin is an orally administered selective sodium-glucose cotransporter 2 (SGLT2) inhibitor under development for the treatment of type 2 diabetes mellitus (T2DM). Dapagliflozin lowers blood glucose through a reduction in renal glucose reabsorption. This study was performed to a...

Descripción completa

Detalles Bibliográficos
Autores principales: Imamura, Akira, Kusunoki, Masahito, Ueda, Shinya, Hayashi, Nobuya, Imai, Yasuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2013
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3687097/
https://www.ncbi.nlm.nih.gov/pubmed/23307267
http://dx.doi.org/10.1007/s13300-012-0016-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3687097/
https://www.ncbi.nlm.nih.gov/pubmed/23307267
http://dx.doi.org/10.1007/s13300-012-0016-5

Ejemplares similares